Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB-positive acute lymphoblastic leukemia patients: A retrospective multicenter study.
Xiaoyan ZhangYaqin WangXin TianLirong SunHua JiangJinhua ChuFen ZhouShuhong ShenShaoyan HuYongjun FangChangcheng LaiXiuli JuXiaoxiao XuXiaowen ZhaiHui JiangMinghua YangAlex W K LeungNing XueYingchi ZhangJun YangChing-Hon PuiJie YuJu GaoQun HuXiaofan ZhuPublished in: Cancer (2024)
Pediatric acute lymphoblastic leukemia patients with PDGFRB fusions are associated with high-risk clinical features such as older age, high white blood cell count at diagnosis, high measurable residual disease after induction therapy, and increased risk of leukemia relapse. Chemotherapy plus tyrosine-kinase inhibitors can improve the complete remission rate and provide an opportunity for lower measurable residual disease (MRD) levels and transplantation for pediatric PDGFRB-positive acute lymphoblastic leukemia (ALL) patients. The MRD level was also a powerful prognostic factor for pediatric PDGFRB-positive ALL patients.
Keyphrases
- prognostic factors
- acute lymphoblastic leukemia
- end stage renal disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- allogeneic hematopoietic stem cell transplantation
- physical activity
- patient reported outcomes
- bone marrow
- acute myeloid leukemia
- radiation therapy
- young adults
- locally advanced
- mesenchymal stem cells
- peripheral blood
- chronic myeloid leukemia